Theravance Biopharma US Revenue and Competitors
Estimated Revenue & Valuation
- Theravance Biopharma US's estimated annual revenue is currently $37.7M per year.
- Theravance Biopharma US's estimated revenue per employee is $155,000
Employee Data
- Theravance Biopharma US has 243 Employees.
- Theravance Biopharma US grew their employee count by -7% last year.
Theravance Biopharma US's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Staff, Development | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | VP, Commercial Strategy | Reveal Email/Phone |
5 | SVP | Reveal Email/Phone |
6 | Head Quality Europe | Reveal Email/Phone |
7 | VP Head Facilities Operations | Reveal Email/Phone |
8 | Head Investor Relations | Reveal Email/Phone |
9 | VP, Biometrics | Reveal Email/Phone |
10 | SVP, General Counsel and Corporate Secretary | Reveal Email/Phone |
Theravance Biopharma US Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Theravance Biopharma US?
Theravance Biopharma is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our pipeline of internally discovered programs is targeted to address significant patient needs. Our research is focused in the areas of inflammation and immunology. We have one approved product, YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
keywords:N/AN/A
Total Funding
243
Number of Employees
$37.7M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Theravance Biopharma US News
New Jersey, United States The Staphylococcal Infection Drugs Market report ... The Medicines Company, Theravance Biopharma, Allergan Plc,...
DUBLIN, April 4, 2022 /PRNewswire/ -- Theravance Biopharma, ... orthostatic hypotension (nOH) with patent protection until 2037 in the US.
DUBLIN, April 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: ... of the Theravance Biopharma group of companies (in the US and...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $48.6M | 251 | -4% | $65M |
#2 | $147.3M | 261 | -2% | $192.5M |
#3 | $95.1M | 262 | 5% | N/A |
#4 | $197.9M | 266 | -11% | $194.5M |
#5 | $29.7M | 270 | 7% | N/A |